The SURPASS Trial Program: Tirzepatide for Type 2 Diabetes

The SURPASS program includes multiple trials (SURPASS-1 through SURPASS-6 and others) designed to evaluate tirzepatide's efficacy and safety for type 2 diabetes across diverse populations and treatment settings. These trials enrolled adults with established type 2 diabetes with suboptimal glycaemic control despite current therapy or treatment-naive individuals. Importantly, SURPASS trials compared tirzepatide against established diabetes therapies, including GLP-1 receptor agonists, insulin, and sulfonylureas, providing head-to-head efficacy comparisons.

The trials used randomised, double-blind, placebo-controlled designs, with some incorporating active comparators (other diabetes medications) rather than placebo. This active-comparator design is particularly valuable because it directly demonstrates tirzepatide's superiority over existing standard-of-care treatments rather than merely showing efficacy above placebo.

SURPASS trials varied in design based on research questions. SURPASS-1 compared tirzepatide to placebo, establishing proof of concept. SURPASS-2 compared tirzepatide to semaglutide (a GLP-1-only agonist), directly testing the dual-agonism hypothesis. SURPASS-3 evaluated tirzepatide versus insulin glargine (a basal insulin). SURPASS-4 tested tirzepatide in combination with other diabetes medications. SURPASS-5 and -6 evaluated tirzepatide in specific populations or treatment contexts.

All trials measured HbA1c—a measure of average blood glucose control over 2-3 months—as the primary endpoint. Secondary endpoints included fasting glucose, weight change, and glycaemic variability. Safety assessments were comprehensive, including adverse events, hypoglycaemia rates, and laboratory monitoring. Trial durations ranged from 24 to 104 weeks, providing both short-term and longer-term efficacy and safety assessments.

Tirzepatide demonstrated robust HbA1c reductions across SURPASS trials. In SURPASS-1, tirzepatide reduced HbA1c by approximately 1.5-1.9 percentage points at the highest dose (15 mg weekly) compared to minimal change with placebo. More importantly, in SURPASS-2, tirzepatide outperformed semaglutide (a GLP-1-only agonist): tirzepatide achieved HbA1c reductions of approximately 2.0-2.1 percentage points while semaglutide achieved approximately 1.7-1.8 percentage points. This ~0.3-0.4 percentage point superiority, though seemingly modest numerically, is clinically significant and consistent with the dual-agonism advantage.

In SURPASS-3, comparing tirzepatide to basal insulin glargine, tirzepatide demonstrated superior HbA1c control with additional weight loss benefit (insulin typically causes weight gain). These comparisons across multiple active comparators establish tirzepatide as an efficacious agent across diverse baseline treatment contexts.

A particularly notable secondary finding was weight loss with tirzepatide in diabetes trials. While glycaemic control is the primary endpoint in diabetes trials, weight loss is a valuable secondary benefit because obesity and type 2 diabetes are intrinsically linked, and weight reduction improves insulin sensitivity and overall metabolic health. Tirzepatide recipients achieved weight loss of approximately 6-8 kg (approximately 5-7% of baseline) in 52-week trials, substantially more than semaglutide recipients and opposite to the weight gain seen with insulin.

Improvements in lipid profiles, blood pressure, and markers of insulin resistance were observed with tirzepatide. Some trials reported improvements in cardiovascular risk markers and renal function indices, though longer-term cardiovascular outcome trials are still ongoing.

The safety profile of tirzepatide in diabetes trials was consistent with the SURMOUNT program. Gastrointestinal side effects (nausea, vomiting, diarrhoea) were more common with tirzepatide than placebo or comparator arms but generally mild to moderate and transient. Importantly, when used as monotherapy or with other non-insulin agents, tirzepatide showed very low rates of hypoglycaemia—comparable to placebo. This glucose-dependent mechanism is a substantial safety advantage.

When tirzepatide was combined with insulin or sulfonylureas (agents that can cause hypoglycaemia), hypoglycaemia risk was higher but remained manageable and comparable to other agents used in combination. No increases in pancreatitis, acute kidney injury, or other serious metabolic events were observed. The safety profile supported approval for use in type 2 diabetes.

SURPASS trials were primarily 52-week studies, with extended follow-up in some cases. Longer-term data (beyond 3-5 years) regarding sustained HbA1c control, metabolic adaptation, and very-late safety signals remain incomplete. Cardiovascular outcome trials (assessing whether tirzepatide reduces heart attacks, strokes, or other major cardiovascular events) are ongoing and have not yet been fully published.

Additionally, trials enrolled predominantly individuals of European descent; data in other ethnic groups and in low-income settings where type 2 diabetes has its greatest burden are limited. Further research in diverse populations will strengthen evidence for tirzepatide's benefit across global populations.